Inebilizumab
- Generic Name
- Inebilizumab
- Brand Names
- Uplizna 3 Vial Kit, Uplizna
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1299440-37-1
- Unique Ingredient Identifier
- 74T7185BMM
- Background
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface...
- Indication
Inebilizumab is indicated for the treatment of aquaporin-4 (AQP4) immunoglobulin-positive (AQP4-IgG) neuromyelitis optica spectrum disorder (NMOSD) in adult patients.
- Associated Conditions
- Neuromyelitis Optica Spectrum Disorders
- Associated Therapies
- -
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis
Amgen presents new data on UPLIZNA for IgG4-RD and KRYSTEXXA for uncontrolled gout at ACR Convergence 2024, highlighting reduced disease activity and shorter infusion times.
Amgen Presents New Data Across Rare Inflammatory Diseases at ACR 2024
Amgen presents new data on UPLIZNA® for IgG4-RD and KRYSTEXXA® for uncontrolled gout at ACR Convergence 2024, highlighting reduced disease activity and shorter infusion times, respectively.
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN ...
Amgen announces positive Phase 3 MINT trial results for UPLIZNA in treating gMG, showing statistically significant efficacy in AChR+ and MuSK+ patients, with a reduction in corticosteroid use and no new safety signals.
Related Clinical Trials:
Uplizna Improved Outcomes Over Placebo in Phase 3 Trials for IgG4-RD, Myasthenia Gravis
Inebilizumab-cdon shows efficacy in treating IgG4-related disease and generalized myasthenia gravis in phase 3 trials, reducing flare risk by 87% and improving daily activities, with no new safety signals identified.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath